---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323652"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2026-07-29T20:05:59+00:00"
generated_at: "2026-07-29T20:07:16.573317+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viking Q2 net loss $128M; Phase 3 obesity trials fully enrolled; cash $502M

## Summary
- Net loss of $128.0M ($1.10/share) vs $65.6M ($0.58) in Q2 2025; R&D spend $115.8M.
- Phase 3 VANQUISH-1 (4,500 patients) and VANQUISH-2 (1,000) for subcutaneous VK2735 fully enrolled.
- Oral VK2735 Phase 3 trial initiation expected in Q4 2026; maintenance dosing data due Q3 2026.
- Phase 1 trial of amylin agonist VK3019 initiated in Q2 2026 after IND clearance.
- Appointed Hubert Chen, M.D., as CMO; Dorothy Gemmell to board; cash $502M at June 30.

## SEC filing metadata
- accession: 0001193125-26-323652
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2026-07-29T20:05:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/0001193125-26-323652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323652
- JSON: https://secwatch.observer/filing/0001193125-26-323652.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.